San Diego-centered Viking Therapeutics marked itself as a serious competitor within the weight loss drug market in February following revealing promising facts from a mid-stage trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when supplied like a weekly injection and in March the company unveiled